Oncology Drug Reference Sheet: Sacituzumab Govitecan-Hziy
Kristine B. LeFebvre MSN, RN, AOCN®
Voice
Description
Initially marketed in April 2020 for treatment of adults with metastatic triple negative breast cancer, sacituzumab govitecan-hziy (Trodelvy®) received an additional approval in 2021 for the treatment of patients with locally advanced or metastatic urothelial cancer with prior treatments.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education